USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ADVANCED TARGETING SYSTEMS, INC.
Address: 10451 Roselle St #300
SAN DIEGO, CA 92121
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,007,606.00 13
SBIR Phase II $4,616,812.00 5

Award List:

Specific Tool for Modeling Neuronal Degeneration

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas Lappi
Award Amount: $96,844.00
Abstract:
Alzheimer's disease (AD) is a common, devastating neurodegenerative disorder characterized by progrcognitive decline. Loss of the cholinergic innervation of limbic structures and the neocortex occursin patients with AD. The degree of cognitive decline has been correlated to the extent of… More

NEW TOOL FOR BASIC NEUROBIOLOGICAL RESEARCH

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,997.00

NEW TOOL FOR BASIC NEUROBIOLOGICAL RESEARCH

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $749,317.00

TOOLS FOR THE DISSECTION OF PAIN TRANSMISSION PATHWAYS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $100,000.00

MAB'S TO TARGET SPECIFIC NEURONAL POPULATIONS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $113,227.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $100,000.00

Targeting Neurons Involved in Chronic Pain Transmission

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $133,547.00
Abstract:
DESCRIPTION (Adapted from applicant's abstract): Chronic pain is an enormous problem in the United States: it is estimated that 30 to 100 million people suffer from it. Often, current treatments are ineffective and the population of sufferers is often described as… More

TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $397,984.00

TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $0.00

A Specific Tool for Targeting Neurodegeneration

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $0.00
Abstract:
DESCRIPTION: (Adapted from the Applicant's Abstract) The Mouse is the species of choice for many neuroscientists because of well-characterized molecular biology and chemistry of its brain, the recent widespread use of transgenic and knockout techniques, and the low cost and… More

A Specific Tool for Targeting Neurodegeneration

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $282,235.00
Abstract:
DESCRIPTION: (Adapted from the Applicant's Abstract) The Mouse is the species of choice for many neuroscientists because of well-characterized molecular biology and chemistry of its brain, the recent widespread use of transgenic and knockout techniques, and the low cost and… More

Drug Development of a Chronic Pain Therapeutic

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): SP-SAP, a conjugate between the peptide neurotransmitter substance P, and the ribosome-inactivating protein, saporin, has been shown, through previous NIH funding, to ablate chronic pain transmission in several rat models. Importantly, acute, reflexive pain… More

Drug Development of a Chronic Pain Therapeutic

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $2,388,923.00
Abstract:
DESCRIPTION (provided by applicant): SP-SAP, a conjugate between the peptide neurotransmitter substance P, and the ribosome-inactivating protein, saporin, has been shown, through previous NIH funding, to ablate chronic pain transmission in several rat models. Importantly, acute, reflexive pain… More

Monoclonal Antibodies to Target Neuronal Populations

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $0.00

Monoclonal Antibodies to Target Neuronal Populations

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $798,353.00

Inhibition of Neurotransmission in Specific Neuronal Populations

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $114,336.00
Abstract:
DESCRIPTION (provided by applicant): In extensive work over the last decade, it has become clear that biologically active molecules can be inserted into specific cell types through targeting to molecules on the cell surface. It is here proposed to direct this technology to specific neuronal cell… More

Selective Activation in Specific Neuronal Populations

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $99,175.00
Abstract:
DESCRIPTION (provided by applicant): Selective Activation in Specific Neuronal Populations Summary: Molecules targeted towards cell surface markers have been used for years to identify specific cell types. It has been demonstrated over the course of the pa st decade that biologically-active… More

Targeting a Poor Prognosis Marker for Tumor Therapy

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas A. Lappi
Award Amount: $150,480.00
Abstract:
DESCRIPTION (provided by applicant): Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic cancers. According to the National Cancer Institute, the s urvival rate for many types of cancer has… More